Science Corp. Announces Long-Term (36 Months) Results of PRIMA BCI Clinical Trial Showing Durable Vision Restoration in Blind Patients Suffering from Geographic Atrophy
ALAMEDA, Calif.--(BUSINESS WIRE)--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced long-term (36 months) followup data from its pivotal PRIMAvera clinical trial (NCT04676854). The results were presented in a late-breaking session at the 26th EURETINA Congress of European retina specialists in Vienna by Mahi Muqit, MD, PhD, Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust and Associate Professor at the Institu